CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Xarelto Rivaroxaban Deep-vein thrombosis without symptomatic pulmonary embolism List with clinical criteria and/or conditions Complete
Xarelto Rivaroxaban Deep-vein thrombosis without symptomatic pulmonary embolism Complete
Prevymis letermovir Cytomegalovirus infection, prophylaxis Reimburse with clinical criteria and/or conditions Complete
Prevymis letermovir Cytomegalovirus infection (CMV), prophylaxis Withdrawn
Kalydeco Ivacaftor Cystic fibrosis, R117H CFTR gating mutation List with criteria/condition Complete
Kalydeco Ivacaftor Cystic fibrosis, G551D mutation List with criteria/condition Complete
Trikafta elexacaftor/tezacaftor/ivacaftor and ivacaftor Cystic fibrosis, F508del or responsive CFTR mutation, 2 years and older Active
Trikafta elexacaftor/tezacaftor/ivacaftor and ivacaftor Cystic fibrosis, F508del CFTR mutation, 6 years and older Reimburse with clinical criteria and/or conditions Complete
Trikafta elexacaftor/tezacaftor/ivacaftor and ivacaftor Cystic fibrosis, F508del CFTR mutation, 2 years and older Reimburse with clinical criteria and/or conditions Complete
Orkambi lumacaftor/ivacaftor Cystic Fibrosis, F508del CFTR mutation in patients 6 years and older Do not reimburse Complete
Last Updated : May 19, 2024